Market Cap | 3.32M | P/E | - | EPS this Y | -10.50% | Ern Qtrly Grth | - |
Income | -12.87M | Forward P/E | -0.40 | EPS next Y | - | 50D Avg Chg | -7.00% |
Sales | 319k | PEG | - | EPS past 5Y | - | 200D Avg Chg | -37.00% |
Dividend | N/A | Price/Book | N/A | EPS next 5Y | - | 52W High Chg | -88.00% |
Recommedations | 2.00 | Quick Ratio | 1.54 | Shares Outstanding | 5.03M | 52W Low Chg | 14.00% |
Insider Own | 1.17% | ROA | -59.85% | Shares Float | 4.97M | Beta | 1.34 |
Inst Own | 3.35% | ROE | -454.34% | Shares Shorted/Prior | 64.18K/58.40K | Price | 0.63 |
Gross Margin | -78.37% | Profit Margin | - | Avg. Volume | 378,661 | Target Price | 8.30 |
Oper. Margin | -6,232.81% | Earnings Date | May 8 | Volume | 46,492 | Change | 2.59% |
Motus GI Holdings, Inc. operates as a medical technology company in the United States. It develops Pure-Vu system, a medical device to facilitate the cleansing of a poorly prepared gastrointestinal tract during the colonoscopy and facilitates upper gastrointestinal endoscopy procedures. The company was formerly known as Eight-Ten Merger Corp. and changed its name to Motus GI Holdings, Inc. in November 2016. Motus GI Holdings, Inc. was founded in 2008 and is based in Fort Lauderdale, Florida.